Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients

被引:0
作者
Masebe, Tracy Madimabi [1 ]
Bessong, Pascal Obong [1 ]
Nwobegahay, Julius [1 ]
Ndip, Roland Ndip [2 ,3 ]
Meyer, Debra [4 ]
机构
[1] Univ Venda, AIDS Virus Res Lab, Dept Microbiol, ZA-0950 Thohoyandou, South Africa
[2] Univ Ft Hare, Dept Biochem & Microbiol, Alice, South Africa
[3] Univ Buea, Dept Life Sci, Buea, Cameroon
[4] Univ Pretoria, Dept Biochem, ZA-0002 Pretoria, South Africa
基金
新加坡国家研究基金会;
关键词
HIV; MDR1; CYP2B6; polymorphisms; South Africa; HIV-INFECTED PATIENTS; CYTOCHROME P4502B6 CYP2B6; PLASMA EFAVIRENZ; GENE; PHARMACOGENETICS; FREQUENCY; POPULATION; PHARMACOKINETICS; MUTATION; THERAPY;
D O I
10.1155/2012/453479
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Data on genetic polymorphisms associated with response to anti-HIVdrugs has accumulated over the years. Information on how polymorphisms influence drug metabolism and transport to target sites is important in guiding dosage or selection of appropriate alternative therapies. This study determined the frequency of MDR1 C3435T and CYP2B6 G516T polymorphisms associated with the transport and metabolism of efavirenz and nevirapine, in a population of South African HIV infected patients. In addition, association of polymorphisms with immunologic and virologic factors was investigated. A 207bp of MDR1 exon 26 and a 161bp of CYP2B6 exon 4 were obtained from patients by polymerase chain reaction. Analysis of population-based sequences of MDR1 revealed a frequency of 89% and 11% of C and T alleles respectively (n = 197; X-2 = 0.974; p = 0.324). Restriction fragment length polymorphism (RFLP) analysis of the CYP2B6 gene revealed a prevalence of 9.5% of GG, 78.4% of GT and 12.1% of TT genotype (n = 199; X-2 = 65.204; p = 0.00). There was no significant difference between immune recovery and decline in viral load (n = 53), with genotype after repeated calculations of analysis of variance (ANOVA).
引用
收藏
页码:43 / 50
页数:8
相关论文
共 36 条
  • [1] MDR1 pharmacogenetics:: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity
    Ameyaw, MM
    Regateiro, F
    Li, T
    Liu, XH
    Tariq, M
    Mobarek, A
    Thornton, N
    Folayan, GO
    Githang'a, J
    Indalo, A
    Ofori-Adjei, D
    Price-Evans, DA
    McLeod, HL
    [J]. PHARMACOGENETICS, 2001, 11 (03): : 217 - 221
  • [2] [Anonymous], 2010, U. S. White Paper to Explore A Grand Challenge for Electricity from Solar, P1
  • [3] A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation
    Ariyoshi, N
    Miyazaki, M
    Toide, K
    Sawamura, Y
    Kamataki, T
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 281 (05) : 1256 - 1260
  • [4] Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates
    Balram, C
    Sharma, A
    Sivathasan, C
    Lee, EJD
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (01) : 78 - 83
  • [5] Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population
    Bernal, ML
    Sinues, B
    Fanlo, A
    Mayayo, E
    [J]. THERAPEUTIC DRUG MONITORING, 2003, 25 (01) : 107 - 111
  • [6] MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa
    Chelule, PK
    Gordon, M
    Palanee, T
    Page, T
    Mosam, A
    Derm, FC
    Coovadia, HM
    Cassol, S
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (02) : 195 - 196
  • [7] CHEN CJ, 1990, J BIOL CHEM, V265, P506
  • [8] Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: An update
    Cressey, Tim R.
    Lallemant, Marc
    [J]. INFECTION GENETICS AND EVOLUTION, 2007, 7 (02) : 333 - 342
  • [9] The genetic variability of MDR1 C3435T polymorphisms in four Southern Chinese populations
    Dong, Qingming
    Xu, Bingying
    Tan, Yi
    Liu, Zheng
    Tian, Linwei
    Zhang, Bao
    Lin, Che-Kit
    Kung, Hsiang-fu
    Sung, Joseph J. Y.
    He, Ming-Liang
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2009, 63 (09) : 658 - 662
  • [10] ESTES KE, 2007, J PHARM PRACT, V20, P234, DOI DOI 10.1177/0897190007304819